Chinese medical expense crowdfunding platform Shuidi raises $24M Series A from Tencent and others, says it has helped raise $140M for 60,000+ patients
Pan Yue / China Money Network :
Context & Ripple Effects
Tencent's lead in Shuidi's $24M Series A puts it behind a medical-expense crowdfunding platform that claims $140M raised for over 60,000 patients — small money by Tencent's standards, but an early position in consumer health finance. The bet aged well on paper: less than two years later Shuidichou returned with a ~$74M Series B, also led by Tencent, claiming $1.8B+ raised across 400M campaigns.
The round also lands inside a broader funding wave in Chinese digital health — online pharmacy Yaoshibang's ~$65.7M Series C, telehealth-and-pharmacy player Miaoshou Doctor's ~$84M Series D, DXY's $500M round, and MediTrust Health's $308M Series C — with Tencent appearing as a repeat backer of the category.
First-order effects
- Shuidi gets Tencent-branded capital and distribution backing to scale its crowdfunding base beyond the 60,000+ patients it has served, while Tencent adds a health-finance asset alongside its social and payments footprint.
Second-order effects
- Crowdfunding platforms become acquisition funnels for adjacent health businesses: the same patients and donors Shuidi aggregates are the audience that later rounds from MediTrust Health, Miaoshou Doctor, and Yaoshibang were built to monetize through payments, telehealth, and pharmacy.
Third-order effects
- If the pattern holds, medical crowdfunding consolidates into full-stack digital health groups where donation flows feed insurance-like payment products and drug sales — with Tencent positioned as the connective investor across the stack rather than a single-platform owner.
The trend: China's digital health funding moved from point solutions like crowdfunding toward integrated payment-pharmacy-telehealth stacks, with Tencent repeatedly anchoring the rounds.